IOncology

Editor’s Note: In recent years, systemic treatment options for HER2-positive breast cancer brain metastases have made meaningful progress, yet substantial unmet clinical needs remain. At the 2025 San Antonio Breast…

Editor's Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…

At the recent ESMO-ASIA Congress, Professor Takayuki delivered an in-depth interpretation of the latest follow-up data from the Asian subgroup of the KEYNOTE-859 study. The presentation explored the long-term clinical value of pembrolizumab plus chemotherapy as a first-line treatment for Asian patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, providing a comprehensive look at the regimen's durable efficacy over a 5-year timeframe.

Editor’s Note: In a recent academic presentation, Prof. Do-Youn Oh (Seoul National University College of Medicine) shared updated long-term results from the Asian subgroup of the Phase III KEYNOTE-859 study,…

Editor’s Note: At a recent GI oncology symposium, Prof. Jung Yong Hong (Samsung Medical Center, South Korea) presented safety results from the Phase 3b SIERRA study, focusing on Asian patients…

Editor’s Note: In an oral presentation selected by the ESMO Asia Scientific Committee, Dr. David Tai (Singapore) presented updated subgroup analyses from the Phase III CheckMate 9DW study, examining the…

Editor’s Note: Despite the success of immune checkpoint inhibitors (ICIs) in GI tumors, immune resistance and the immunosuppressive tumor microenvironment (TME) remain major barriers. At a recent symposium, Prof. Kohei…

Editor’s note: From its early focus on “standards, safety and standardized practice” to today’s deep integration of clinical, basic, and translational research, the 8th Shanghai International Medical Oncology Symposium (SIMOS)…

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…

From December 5 to 7, 2025, the highly anticipated European Society for Medical Oncology Asia Congress (ESMO Asia 2025) was grandly held in Singapore. During the Mini Oral Session: Gastrointestinal Tumours, Professor George Lau, Chairman of the Hong Kong Humanity Medical Group and Director of the Humanity Medical Clinical Research CenterSenior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Center, Principal Investigator of the Humanity and Health Clinical Trial Center, as well as a physician Honorary Professor and Senior Consultant at Zhongshan Hospital Affiliated to Fudan University, was invited to deliver an oral presentation. For the first time, he shared the research data on the treatment of Asian patients with unresectable hepatocellular carcinoma (HCC) using Tremelimumab in combination with Durvalumab. This study is based on a sample that more closely reflects the epidemiological characteristics and disease spectrum of Asian patients, providing high-quality evidence-based medical evidence with targeted relevance. It lays a solid foundation for optimizing and advancing the individualization and precision of liver cancer treatment strategies in this region.